Drug Profile
Research programme: antibody-based cancer therapeutics and diagnostics - CureMeta
Latest Information Update: 28 Nov 2018
Price :
$50
*
At a glance
- Originator CureMeta
- Developer Barbara Ann Karmanos Cancer Institute; CureMeta
- Class Antibodies; Antibody diagnostics
- Mechanism of Action Immunomodulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Cancer
Most Recent Events
- 28 Nov 2018 No recent reports of development identified for preclinical development in Cancer(Diagnosis, Metastatic disease) in USA
- 28 Apr 2018 No recent reports of development identified for research development in Cancer(Metastatic disease) in USA